Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Cytokinetics

    NASDAQ: CYTK · Real-Time Price · USD
    33.75
    -0.63 (-1.83%)
    At close: Jun 16, 2025, 3:59 PM
    33.78
    0.09%
    After-hours: Jun 16, 2025, 04:20 PM EDT

    Cytokinetics Statistics

    Share Statistics

    Cytokinetics has 119.43M shares outstanding. The number of shares has increased by 3.27% in one year.

    Shares Outstanding

    n/a
    		 119.43M

    Shares Change (YoY)

    n/a
    		 3.27%

    Shares Change (QoQ)

    n/a
    		 0.34%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 116.73M

    Failed to Deliver (FTD) Shares

    n/a
    		 30

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 14.5M, so 12.14% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 14.5M

    Short % of Shares Out

    n/a
    		 12.14%

    Short % of Float

    n/a
    		 15.84%

    Short Ratio (days to cover)

    n/a
    		 8.46

    Valuation Ratios

    The PE ratio is -8.94 and the forward PE ratio is -6.79. Cytokinetics's PEG ratio is 2.56.

    PE Ratio

    n/a
    		 -8.94

    Forward PE

    n/a
    		 -6.79

    PS Ratio

    n/a
    		 285.13

    Forward PS

    n/a
    		 2.6

    PB Ratio

    n/a
    		 -38.91

    P/FCF Ratio

    n/a
    		 -13.18

    PEG Ratio

    n/a
    		 2.56
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Cytokinetics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 6.17, with a Debt / Equity ratio of -5.83.

    Current Ratio

    n/a
    		 6.17

    Quick Ratio

    n/a
    		 6.17

    Debt / Equity

    n/a
    		 -5.83

    Debt / EBITDA

    n/a
    		 -1.6

    Debt / FCF

    n/a
    		 -1.97

    Interest Coverage

    n/a
    		 -6.2

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $37,096.39

    Profits Per Employee

    n/a
    		 $-1,183,787.15

    Employee Count

    n/a
    		 498

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -36.06% in the last 52 weeks. The beta is 0.59, so Cytokinetics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.59

    52-Week Price Change

    n/a
    		 -36.06%

    50-Day Moving Average

    n/a
    		 34.83

    200-Day Moving Average

    n/a
    		 45.99

    Relative Strength Index (RSI)

    n/a
    		 52.46

    Average Volume (20 Days)

    n/a
    		 2,092,407

    Income Statement

    In the last 12 months, Cytokinetics had revenue of 18.47M and earned -589.53M in profits. Earnings per share was -5.26.

    Revenue

    n/a
    		 18.47M

    Gross Profit

    n/a
    		 8.94M

    Operating Income

    n/a
    		 -536.25M

    Net Income

    n/a
    		 -589.53M

    EBITDA

    n/a
    		 -493.48M

    EBIT

    n/a
    		 -503.01M

    Earnings Per Share (EPS)

    n/a
    		 -5.26
    Full Income Statement

    Balance Sheet

    The company has 94.86M in cash and 788.68M in debt, giving a net cash position of -693.82M.

    Cash & Cash Equivalents

    n/a
    		 94.86M

    Total Debt

    n/a
    		 788.68M

    Net Cash

    n/a
    		 -693.82M

    Retained Earnings

    n/a
    		 -2.7B

    Total Assets

    n/a
    		 1.26B

    Working Capital

    n/a
    		 796.33M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -395.89M and capital expenditures -3.91M, giving a free cash flow of -399.8M.

    Operating Cash Flow

    n/a
    		 -395.89M

    Capital Expenditures

    n/a
    		 -3.91M

    Free Cash Flow

    n/a
    		 -399.8M

    FCF Per Share

    n/a
    		 -3.57
    Full Cash Flow Statement

    Margins

    Gross margin is 48.41%, with operating and profit margins of -2902.72% and -3191.11%.

    Gross Margin

    n/a
    		 48.41%

    Operating Margin

    n/a
    		 -2902.72%

    Pretax Margin

    n/a
    		 -3191.11%

    Profit Margin

    n/a
    		 -3191.11%

    EBITDA Margin

    n/a
    		 -2671.23%

    EBIT Margin

    n/a
    		 -2902.72%

    FCF Margin

    n/a
    		 -2164.1%

    Dividends & Yields

    CYTK does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CYTK is $72, which is 113.3% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $72

    Price Target Difference

    n/a
    		 113.3%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 15
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jun 25, 2013. It was a backward split with a ratio of 1:6.

    Last Split Date

    n/a
    		 Jun 25, 2013

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:6

    Scores

    Altman Z-Score

    n/a
    		 -2.35

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist